Literature DB >> 15173875

Progress on new vaccine strategies for the immunotherapy and prevention of cancer.

Jay A Berzofsky1, Masaki Terabe, SangKon Oh, Igor M Belyakov, Jeffrey D Ahlers, John E Janik, John C Morris.   

Abstract

In recent years, great strides in understanding and regulating the immune system have led to new hope for harnessing its exquisite specificity to destroy cancer cells without affecting normal tissues. This review examines the fundamental immunologic advances and the novel vaccine strategies arising from these advances, as well as the early clinical trials studying new approaches to treat or prevent cancer.

Entities:  

Mesh：

Substances：

Year:  2004        PMID： 15173875      PMCID： PMC419494          DOI： 10.1172/JCI21926

Source DB:  PubMed          Journal:  J Clin Invest        ISSN： 0021-9738            Impact factor:   14.808


  123 in total

1.  Suppressor effector function of CD4+CD25+ immunoregulatory T cells is antigen nonspecific.

Authors:  A M Thornton; E M Shevach
Journal:  J Immunol       Date:  2000-01-01       Impact factor: 5.422

2.  Molecular basis of T cell inactivation by CTLA-4.

Authors:  K M Lee; E Chuang; M Griffin; R Khattri; D K Hong; W Zhang; D Straus; L E Samelson; C B Thompson; J A Bluestone
Journal:  Science       Date:  1998-12-18       Impact factor: 47.728

3.  CD40 ligation and phagocytosis differently affect the differentiation of monocytes into dendritic cells.

Authors:  Michelle Rosenzwajg; Frédéric Jourquin; Ludovic Tailleux; Jean Claude Gluckman
Journal:  J Leukoc Biol       Date:  2002-12       Impact factor: 4.962

4.  T-cell responses against tyrosinase 368-376(370D) peptide in HLA*A0201+ melanoma patients: randomized trial comparing incomplete Freund's adjuvant, granulocyte macrophage colony-stimulating factor, and QS-21 as immunological adjuvants.

Authors:  Susanne G Schaed; Virginia M Klimek; Katherine S Panageas; Cristina M Musselli; Leah Butterworth; Wen-Jen Hwu; Philip O Livingston; Linda Williams; Jonathan J Lewis; Alan N Houghton; Paul B Chapman
Journal:  Clin Cancer Res       Date:  2002-05       Impact factor: 12.531

5.  Phase I trial of a B7-1 (CD80) gene modified autologous tumor cell vaccine in combination with systemic interleukin-2 in patients with metastatic renal cell carcinoma.

Authors:  Scott J Antonia; John Seigne; Jose Diaz; Carlos Muro-Cacho; Martine Extermann; Mary Jane Farmelo; Maria Friberg; Marwan Alsarraj; J J Mahany; Julio Pow-Sang; Alan Cantor; William Janssen
Journal:  J Urol       Date:  2002-05       Impact factor: 7.450

6.  Idiotype vaccination using dendritic cells after autologous peripheral blood progenitor cell transplantation for multiple myeloma.

Authors:  A Liso; K E Stockerl-Goldstein; S Auffermann-Gretzinger; C J Benike; V Reichardt; A van Beckhoven; R Rajapaksa; E G Engleman; K G Blume; R Levy
Journal:  Biol Blood Marrow Transplant       Date:  2000       Impact factor: 5.742

7.  Safety and immunogenicity of a DNA vaccine encoding carcinoembryonic antigen and hepatitis B surface antigen in colorectal carcinoma patients.

Authors:  Robert M Conry; David T Curiel; Theresa V Strong; Susan E Moore; Karen O Allen; Daunte L Barlow; Denise R Shaw; Albert F LoBuglio
Journal:  Clin Cancer Res       Date:  2002-09       Impact factor: 12.531

8.  High avidity CTLs for two self-antigens demonstrate superior in vitro and in vivo antitumor efficacy.

Authors:  H J Zeh; D Perry-Lalley; M E Dudley; S A Rosenberg; J C Yang
Journal:  J Immunol       Date:  1999-01-15       Impact factor: 5.422

9.  Murine dendritic cells loaded in vitro with soluble protein prime cytotoxic T lymphocytes against tumor antigen in vivo.

Authors:  P Paglia; C Chiodoni; M Rodolfo; M P Colombo
Journal:  J Exp Med       Date:  1996-01-01       Impact factor: 14.307

10.  A nonapeptide encoded by human gene MAGE-1 is recognized on HLA-A1 by cytolytic T lymphocytes directed against tumor antigen MZ2-E.

Authors:  C Traversari; P van der Bruggen; I F Luescher; C Lurquin; P Chomez; A Van Pel; E De Plaen; A Amar-Costesec; T Boon
Journal:  J Exp Med       Date:  1992-11-01       Impact factor: 14.307
View more
  56 in total

Review 1.  Strategies to use immune modulators in therapeutic vaccines against cancer.

Authors:  Jay A Berzofsky; Masaki Terabe; Lauren V Wood
Journal:  Semin Oncol       Date:  2012-06       Impact factor: 4.929

2.  DNA plasmid production in different host strains of Escherichia coli.

Authors:  Adam Singer; Mark A Eiteman; Elliot Altman
Journal:  J Ind Microbiol Biotechnol       Date:  2009-01-10       Impact factor: 3.346

Review 3.  Multifunctional nanoparticles for cancer immunotherapy.

Authors:  Tayebeh Saleh; Seyed Abbas Shojaosadati
Journal:  Hum Vaccin Immunother       Date:  2016-02-22       Impact factor: 3.452

4.  Optimal epitope composition after antigen screening using a live bacterial delivery vector: application to TRP-2.

Authors:  Madiha Derouazi; Yan Wang; Raphaël Marlu; Olivier Epaulard; Jean-François Mayol; Nicolas Pasqual; Audrey Le Gouellec; Benoit Polack; Bertrand Toussaint
Journal:  Bioeng Bugs       Date:  2010 Jan-Feb

5.  Systemic blockade of transforming growth factor-beta signaling augments the efficacy of immunogene therapy.

Authors:  Samuel Kim; George Buchlis; Zvi G Fridlender; Jing Sun; Veena Kapoor; Guanjun Cheng; Andrew Haas; Hung Kam Cheung; Xiamei Zhang; Michael Corbley; Larry R Kaiser; Leona Ling; Steven M Albelda
Journal:  Cancer Res       Date:  2008-12-15       Impact factor: 12.701

6.  Preparation and characterization of innovative protein-coated poly(methylmethacrylate) core-shell nanoparticles for vaccine purposes.

Authors:  Rebecca Voltan; Arianna Castaldello; Egidio Brocca-Cofano; Giuseppe Altavilla; Antonella Caputo; Michele Laus; Katia Sparnacci; Barbara Ensoli; Silvia Spaccasassi; Marco Ballestri; Luisa Tondelli
Journal:  Pharm Res       Date:  2007-05-03       Impact factor: 4.200

Review 7.  Immunotherapy of childhood cancer: from biologic understanding to clinical application.

Authors:  Alan S Wayne; Christian M Capitini; Crystal L Mackall
Journal:  Curr Opin Pediatr       Date:  2010-02       Impact factor: 2.856

8.  IMMUNOCAT-a data management system for epitope mapping studies.

Authors:  Jo L Chung; Jian Sun; John Sidney; Alessandro Sette; Bjoern Peters
Journal:  J Biomed Biotechnol       Date:  2010-05-17

9.  Interleukin-13 receptor α2 DNA prime boost vaccine induces tumor immunity in murine tumor models.

Authors:  Hideyuki Nakashima; Toshio Fujisawa; Syed R Husain; Raj K Puri
Journal:  J Transl Med       Date:  2010-11-10       Impact factor: 5.531

10.  Inhibition of Lewis lung carcinoma growth by Toxoplasma gondii through induction of Th1 immune responses and inhibition of angiogenesis.

Authors:  Ju Ock Kim; Sung Soo Jung; Sun Young Kim; Tae Yun Kim; Dae Whan Shin; Jae Ho Lee; Young Ha Lee
Journal:  J Korean Med Sci       Date:  2007-09       Impact factor: 2.153
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.